Tolerability/PoP Study in Allergic Rhinitis After Intranasal Administration of AZD8848

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The primary purpose is to investigate tolerability/safety of repeated weekly doses of AZD8848 administered intranasally to seasonal allergic rhinitis patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Patients with a history of birch and/ or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test)

• Patients with need of treatment for their nasal symptoms during the pollen season

Exclusion Criteria:

• Clinical relevant disease or abnormality (past or present) - other than allergic rhinitis

• Symptomatic perennial allergic or non-allergic rhinitis

• A history of asthma